Drug profile · INN
ziconotide
PRIALT
ziconotide (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker.
EMA: approved Nervous system (N02) N02BG08
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ziconotide
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
ziconotide (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker.
Key facts
INN ziconotide
Brand PRIALT
Mechanism Voltage-gated N-type calcium channel alpha-1B subunit blocker
Target Voltage-dependent N-type calcium channel subunit alpha-1B
Therapeutic class Nervous system (N02)
ATC code N02BG08
Mechanism of action
Voltage-gated N-type calcium channel alpha-1B subunit blocker
Primary target: Voltage-dependent N-type calcium channel subunit alpha-1B
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ziconotide?
ziconotide (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker.
What is the brand name for ziconotide?
PRIALT is a marketed brand name for ziconotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.